Abstract | BACKGROUND: METHODS: Patients were randomly assigned to receive either subcutaneous enoxaparin 4000 anti- factor Xa IU/0.4 mL twice daily or oral aspirin 200 mg daily for 10 days. After day 10, all subjects received aspirin 100 mg once daily for 6 months. We assessed whether LMWH was superior to aspirin in preventing END and VTE within the first 10 days after index stroke and evaluated 6-month outcomes. FINDINGS: Of the total 1368 patients, 7.89% suffered from END, and 2.85% suffered from deep-vein thrombosis during the first 10 days, with a significance difference between the LMWH group and aspirin group (3.95%, 1.46% versus 11.82%, 4.23%, respectively). At 6 months, there was a significant difference in the frequency of good outcomes among patients over the median age of 70 years ( LMWH 63.8% versus aspirin 44.6%). The benefit of LMWH was also significant in patients with symptomatic stenosis of the posterior circulation and basilar artery (75.2% and 82% for LMWH versus 40.5% and 48% for aspirin, respectively). CONCLUSIONS:
|
Authors | Xingyang Yi, Jing Lin, Chun Wang, Biao Zhang, Wanzhang Chi |
Journal | Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association
(J Stroke Cerebrovasc Dis)
Vol. 23
Issue 6
Pg. 1537-44
(Jul 2014)
ISSN: 1532-8511 [Electronic] United States |
PMID | 24656240
(Publication Type: Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
|
Copyright | Copyright © 2014 National Stroke Association. All rights reserved. |
Chemical References |
- Anticoagulants
- Enoxaparin
- Aspirin
|
Topics |
- Aged
- Aged, 80 and over
- Anticoagulants
(therapeutic use)
- Aspirin
(therapeutic use)
- Brain Ischemia
(complications, drug therapy)
- Enoxaparin
(therapeutic use)
- Female
- Humans
- Male
- Middle Aged
- Nervous System Diseases
(drug therapy, etiology, prevention & control)
- Stroke
(complications, drug therapy)
- Treatment Outcome
- Venous Thromboembolism
(drug therapy, etiology, prevention & control)
|